Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Blueprint Medicines Corp (BPMC)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Blueprint Medicines Corp's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
88.38 +2.29    +2.66%
17/04 - Closed. Currency in USD ( Disclaimer )
After Hours
86.62
-1.76
-1.99%
16:42:20 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 727,990
  • Bid/Ask: 86.62 / 93.96
  • Day's Range: 86.76 - 89.69
Blueprint Medicines Corp 88.38 +2.29 +2.66%

BPMC Balance Sheet

 
Featured here, the Balance Sheet for Blueprint Medicines Corp, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Balance Sheet
Collapse All
Period Ending: 2023
31/12
 2023
30/09
 2023
30/06
 2023
31/03
Total Current Assets 808.39 808.17 811.34 900.34
Cash and Short Term Investments 710.64 712.98 722.63 822.16
Cash - - - -
Cash & Equivalents 71.29 55.97 75.53 169.72
Short Term Investments 639.36 657.01 647.11 652.44
Total Receivables, Net 43.18 41.25 38.27 31.3
Accounts Receivables - Trade, Net 43.18 41.25 38.27 31.3
Total Inventory 21.22 16.46 17.02 17.52
Prepaid Expenses 33.35 37.48 33.42 29.36
Other Current Assets, Total - - - -
Total Assets 1049.25 1105.3 1106.44 1220.37
Property/Plant/Equipment, Total - Net 115.65 115.84 114.49 113.41
Property/Plant/Equipment, Total - Gross 154.14 - - -
Accumulated Depreciation, Total -38.49 - - -
Goodwill, Net - - - -
Intangibles, Net - - - -
Long Term Investments 84.32 142.03 141.72 166.94
Note Receivable - Long Term - - - -
Other Long Term Assets, Total 40.89 39.26 38.9 39.68
Other Assets, Total 617.4 632.22 625.86 638.66
Total Current Liabilities 214.92 197.38 169.03 172.68
Accounts Payable 4.71 6.96 6.98 10.56
Payable/Accrued - - - -
Accrued Expenses 110.53 94.34 87.61 96.7
Notes Payable/Short Term Debt - - - -
Current Port. of LT Debt/Capital Leases 81.41 76.98 57.56 49.65
Other Current liabilities, Total 18.28 19.11 16.88 15.77
Total Liabilities 918.64 902.69 795.32 806.07
Total Long Term Debt 610.96 613.17 531.08 535.35
Long Term Debt 610.96 613.17 531.08 535.35
Capital Lease Obligations - - - -
Deferred Income Tax - - - -
Minority Interest - - - -
Other Liabilities, Total -144.26 -294.91 -193.87 -191.04
Total Equity 130.61 202.61 311.13 414.3
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 0.061 0.061 0.061 0.06
Additional Paid-In Capital 2473.98 2434.26 2410.6 2381.36
Retained Earnings (Accumulated Deficit) -2339.94 -2229.02 -2095.31 -1962.52
Treasury Stock - Common - - - -
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total -3.5 -2.68 -4.22 -4.6
Total Liabilities & Shareholders' Equity 1049.25 1105.3 1106.44 1220.37
Total Common Shares Outstanding 61.15 60.74 60.64 60.42
Total Preferred Shares Outstanding - - - -
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

BPMC Comments

Write your thoughts about Blueprint Medicines Corp
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Alejandro Pe
Alejandro Pe Jun 16, 2021 4:12PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
There we go. Not big profit but a profit in a red day for the industry.
Reply
0 0
Report
Alejandro Pe
Alejandro Pe Jun 15, 2021 10:10AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Anyone loading for tomorrow? I am.
Reply
0 0
Report
Ronen xyz
Ronen xyz Jun 12, 2021 11:39AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
bought on the dip, fda going to spike the price
Reply
1 0
Report
Ronen xyz
Ronen xyz Jun 12, 2021 11:39AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
where is the spike ?
Reply
0 0
Report
Alejandro Pe
Alejandro Pe Jun 10, 2021 5:16PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00247-3/fulltext
Reply
0 0
Report
Alejandro Pe
Alejandro Pe Jun 09, 2021 9:40AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
PDUFA date coming up
Reply
1 0
Report
Juan Carlos Gutierrez
Juan Carlos Gutierrez Jul 14, 2020 3:23PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
the average target price is 93.5 and the high target price is 122 why is nobody buying?
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email